



## **Alder Biopharmaceuticals Appoints Clay B. Siegall, Ph.D. to Board**

**Bothell, Washington, March 10, 2006**—Alder Biopharmaceuticals Inc., an early stage antibody therapeutics company, today announced the appointment of Clay B. Siegall, Ph.D., to its board of directors. “Dr. Siegall is an industry leader and a pioneer in the research and development of targeted cancer therapies,” said Dr. Randall Schatzman, Alder CEO and co-founder. “He brings deep experience in the field of antibody therapeutics, and his entrepreneurial work with Seattle Genetics has given him extensive, firsthand knowledge of how to build a successful biotechnology company. We’re excited to add his insights and knowledge to our board.”

Dr. Siegall brings nearly 20 years of experience in cancer research and therapeutic drug development to Alder. His expertise is coupled with the operational, financial and practical experience of running Seattle Genetics, Inc. (Nasdaq: SGEN), which he co-founded in 1998 and currently leads as President, Chief Executive Officer, and member of the board. Under his leadership, Seattle Genetics has developed a diverse portfolio of clinical and preclinical product candidates targeting a variety of cancer and autoimmune indications. Seattle Genetics is also a recognized leader in antibody technologies, notably its antibody-drug conjugate (ADC) platform. Dr. Siegall has also guided Seattle Genetics’ capital-raising activities, securing more than \$230 million through public and private financings, including the company’s initial public offering in 2001. In addition, the company has entered into multiple strategic collaborations, including agreements with Genentech, MedImmune, CuraGen, Bayer and PDL BioPharma that have generated over \$50 million since 2001.

Prior to co-founding Seattle Genetics, Dr. Siegall was with the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997 and the National Cancer Institute, National Institutes of Health from 1988 to 1991. Dr. Siegall received a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland.

Commenting on his appointment, Dr. Siegall said, “I’m excited to join Alder at this important juncture. Alder’s technologies have strong potential to impact the field of antibody therapeutics. I look forward to working with Alder’s talented team as they begin to capitalize on encouraging early results.”

Alder’s unique contribution to the field of antibody therapeutics involves a platform of proprietary antibody technologies that industrializes the approach to developing, selecting and manufacturing antibody therapeutics. Alder’s technologies have the potential to dramatically accelerate progress to the clinic while at the same time providing an inexpensive and rapid route through product manufacturing.

For more information or to set up a non-disclosure agreement to learn about Alder’s proprietary technologies in more detail, please contact Mark Litton, Chief Business Officer, at (425) 205-2920 or [litton@alderbio.com](mailto:litton@alderbio.com).

**About Alder**

Founded in January 2004, Alder Biopharmaceuticals uniquely identifies, develops, and manufactures novel antibody therapeutics to alleviate human suffering in the autoimmune and inflammatory disease areas, with extensions into certain forms of cancer. Alder's management team combines decades of industry experience with a proven track record for identifying and developing novel antibody therapeutics. The company completed a Series A financing led by Sevin Rosen Funds and other investors in August 2005. Today the company is actively engaged in developing its own proprietary therapeutics and enabling partners through out-licensing of its technologies. For more information, visit [www.alderbio.com](http://www.alderbio.com).

**Media and Industry Inquiries:**

Mark Litton  
Chief Business Officer, Alder Biopharmaceuticals Inc.  
(425) 205-2920  
[litton@alderbio.com](mailto:litton@alderbio.com)

**Investor Relations:**

Randall Schatzman, Ph.D.  
CEO, Alder Biopharmaceuticals Inc.  
(425) 205-2910  
[schatzman@alderbio.com](mailto:schatzman@alderbio.com)

© 2006 Alder Biopharmaceuticals, Inc. Data subject to change.